Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Lebon

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Cancers|May 5, 2021
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated IntensivelyMaël Heiblig, Nicolas Duployez, Alice Marceau, et al.
Haematologica|August 16, 2019
PIEZO1 activation delays erythroid differentiation of normal and hereditary xerocytosis-derived human progenitor cellsAlexis Caulier, Nicolas Jankovsky, Yohann Demont, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Blood Advances|April 8, 2025
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase Ib CIMON trialFlorent Malard, Sylvain Thepot, Thomas Cluzeau, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Leukemia Research|May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMCHyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Leukemia|June 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaDelphine Lebon, Audrey Da Rocha, Bruno Cassinat, et al.
British Journal of Haematology|May 29, 2023
Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experienceEtienne Crickx, Mikael Ebbo, Etienne Rivière, et al.
European Journal of Haematology|May 15, 2025
Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic ProfilesLaurène Fenwarth, Benjamin Podvin, Loïc Vasseur, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Cancers|May 5, 2021
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated IntensivelyMaël Heiblig, Nicolas Duployez, Alice Marceau, et al.
Haematologica|August 16, 2019
PIEZO1 activation delays erythroid differentiation of normal and hereditary xerocytosis-derived human progenitor cellsAlexis Caulier, Nicolas Jankovsky, Yohann Demont, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Blood Advances|April 8, 2025
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase Ib CIMON trialFlorent Malard, Sylvain Thepot, Thomas Cluzeau, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Leukemia Research|May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMCHyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Leukemia|June 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaDelphine Lebon, Audrey Da Rocha, Bruno Cassinat, et al.
British Journal of Haematology|May 29, 2023
Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experienceEtienne Crickx, Mikael Ebbo, Etienne Rivière, et al.
European Journal of Haematology|May 15, 2025
Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic ProfilesLaurène Fenwarth, Benjamin Podvin, Loïc Vasseur, et al.
Pageof 5